Prediction: 3 Stocks Berkshire Hathaway Will Add to Its Portfolio After Warren Buffett Steps Down as CEO

By next year, Berkshire Hathaway will have a new CEO in Greg Abel.
Berkshire could have multiple new holdings as Abel may want to put his stamp on the company.
There are some solid blue-chip stocks that aren't in Berkshire's portfolio that arguably should be in there already.
10 stocks we like better than Microsoft ›
Next year, Berkshire Hathaway will have a new CEO. Warren Buffett, who has been in charge for decades, is stepping down and Greg Abel will be taking over. It's a monumental shift for the business, and while there may not necessarily be drastic changes in the day-to-day operations, there could be some adjustments to Berkshire's holdings.
There are three stocks that I think Abel should consider adding to Berkshire's portfolio once he takes over: Microsoft (NASDAQ: MSFT), Enbridge (NYSE: ENB), and Nvidia (NASDAQ: NVDA). Here's why these stocks are great long-term investments and why they fit the Berkshire mold.
Buffett distanced himself from Microsoft because of his close association with co-founder Bill Gates. But with Buffett no longer at the helm, it opens the path for Berkshire to create a position in Microsoft under Abel.
Microsoft is the type of business that checks all the boxes for Berkshire. It has solid fundamentals, many growth opportunities, and a strong brand that is known all over the world, giving it a fantastic competitive moat.
In the trailing 12 months, the software company generated more than $270 billion in revenue, amassing nearly $97 billion in profit along the way. Microsoft is a leading company in artificial intelligence (AI) and cloud computing, and its office software is a staple in many businesses around the world. This is an excellent stock for investors to own for the long haul, and I think it may just be a matter of time before it finds its way into Berkshire's holdings.
With Abel being from Canada and having strong roots in Alberta, I think he'll be inclined to put his stamp on Berkshire. And what better way to do so than by opening up a position in a top oil and gas company from Canada -- Enbridge. Berkshire is no stranger to the sector and holds multiple stocks from there.
Enbridge is known for its consistency and long-term dependability, which is why it also looks like a model Berkshire-type investment. This year, the company expects to meet or exceed its financial guidance, and if it does, it'll be the 20th consecutive year that Enbridge has done so. Few companies can generate that kind of consistency. And Buffett has always valued predictability and stability in businesses.
The pipeline company generated revenue totaling just under 61 billion Canadian dollars over the trailing 12 months. And with Enbridge closing on multiple acquisitions in the U.S. within the past year few years, its financials could look even better in the future. Along with an attractive dividend that yields nearly 6%, this is a stock that can be ideal for any type of long-term investor. Enbridge is another stock I expect may be a staple in Berkshire's portfolio once Abel is at the helm.
For years, iPhone maker Apple has been the top holding in Berkshire's portfolio. But the company has arguably been losing its luster due to a fumbled AI rollout and delaying key features on its latest phones. And it highlights much more than that: a lack of innovation. At the very least, it's lagging behind its key rivals.
A changing of the guard may be overdue at Berkshire. While Buffett has long been a fan of Apple's business, Abel may see an opportunity to change that up. Investing in Nvidia is a move that could make much more sense. Even for people who are unfamiliar with AI, investors have come to know about Nvidia's dominance in the chip world, and I believe it now has the strong brand that Apple once did, which is synonymous with innovation.
Nvidia has dominant market share in the AI chip market, and its fundamentals are incredible. Over the past four quarters, it has net a profit of $77 billion on revenue of nearly $149 billion. Given its impressive market position and huge profit margins, it seems unfathomable that the stock isn't in Berkshire's portfolio already. I can only assume that it's because Buffett may not want too much exposure to tech or that he's simply too unfamiliar with it.
For Abel, however, this can be yet another opportunity for him to change up Berkshire's holdings with more growth-oriented businesses. While Apple may have performed well over the past decade, it may no longer make sense for it to be Berkshire's top holding. Nvidia could be a much better fit.
Before you buy stock in Microsoft, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Microsoft wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,102!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $882,344!*
Now, it's worth noting Stock Advisor's total average return is 996% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of June 9, 2025
David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Apple, Berkshire Hathaway, Enbridge, Microsoft, and Nvidia. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
Prediction: 3 Stocks Berkshire Hathaway Will Add to Its Portfolio After Warren Buffett Steps Down as CEO was originally published by The Motley Fool

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Upturn

25 minutes ago

• Business Upturn

European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept)

REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for marketing in the European Economic Area, that includes the 27 member states of the European Union, in addition to Norway, Iceland and Lichtenstein. 'CHMP's positive opinion takes us a step closer to being able to market our proposed biosimilar in Europe, which is excellent news for patients and their caregivers. Alvotech looks forward to increasing access to this vital biologic treatment for eye disorders,' said Joseph McClellan, Chief Scientific Officer of Alvotech. Advertisement 'We are pleased with the CHMP's positive opinion, which marks an important milestone in our mission to bring high-quality, specialist medicines to patients across Europe,' said Nick Warwick, Chief Medical Officer of Advanz Pharma. The CHMP opinion recommends granting of a marketing authorization for AVT06 intended for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DME) and visual impairment due to myopic choroidal neovascularisation (myopic CNV). Alvotech is responsible for the development and commercial supply of the proposed biosimilar. Advanz Pharma is responsible for registration and has exclusive commercialization rights for most countries in Europe. In 2024, global sales of Eylea® were about US$9 billion, and one third of these sales were in Europe [1]. In January 2024 Alvotech announced positive top-line results from a confirmatory clinical study with AVT06 (AVT06-GL-C01) comparing the efficacy, safety, and immunogenicity of the proposed biosimilar to Eylea® in patients with neovascular (wet) AMD. The study met its primary endpoint, with results demonstrating therapeutic equivalence between Alvotech's biosimilar candidate and Eylea® [2]. Alvotech is also developing AVT29, a proposed biosimilar to Eylea® HD, a higher dose (aflibercept 8 mg) aflibercept. Advanz has licensed the distribution rights from Alvotech for both biosimilar candidates, for the same territory. About AVT06 (aflibercept) AVT06 is a recombinant fusion protein and a biosimilar candidate to Eylea® (aflibercept), which binds vascular endothelial growth factors (VEGF), inhibiting the binding and activation of VEGF receptors, neovascularization, and vascular permeability [3]. AVT06 is an investigational product and has not received regulatory approval in any country. Biosimilarity has not been established by regulatory authorities and is not claimed. Sources [1] Global Data and IQVIA [2] Agostini, H. (2025). A randomized, double-masked parallel-group, multicenter clinical study evaluating the efficacy and safety of the biosimilar candidate AVT06 compared to the reference product aflibercept in participants with neovascular age-related macular degeneration. Expert Opinion on Biological Therapy, 1–15. [3] Use of trademarks Elyea® is a registered trademark of Regeneron Pharmaceuticals Inc. and Bayer AG. About Alvotech Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech's current pipeline includes eight disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech's commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit . None of the information on the Alvotech website shall be deemed part of this press release. About Advanz Pharma Partner of choice in specialty, hospital, and rare disease medicines. Advanz Pharma is a global pharmaceutical company with the purpose to improve patients' lives by providing and enhancing the specialty, hospital, and rare disease medicines they depend on. Our headquarters are in London, UK. We have commercial sales in more than 90 countries globally and have a direct commercial presence in more than 20 countries, including key countries in Europe, the US, Canada, and Australia, a Centre of Excellence in Mumbai, India, as well as an established global distribution and commercialization partner network. Advanz Pharma's product portfolio and pipeline comprises innovative medicines, biosimilars & specialty generics, and originator brands. Our products cover a broad range of therapeutic areas, including hepatology, rheumatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and, more broadly, rare disease medicines. Our ambition is to be a partner of choice for the commercialization of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia. In line with our ambition, we are partnering with biopharma and development companies to bring medicines to patients. We can only achieve this due to our dedicated and highly qualified employees, acting in line with our company values of entrepreneurship, speed, and integrity. Alvotech Forward Looking Statements Certain statements in this communication may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the future financial or operating performance of Alvotech and may include, for example, Alvotech's expectations regarding future growth, results of operations, performance, future capital and other expenditures, competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future events, regulatory review and interactions, the satisfactory responses to the FDA's inspection findings and resolution of other deficiencies conveyed following the re-inspection of Alvotech's manufacturing site, the potential approval, including for AVT02, AVT04, and the product candidates in scope of the partnership with Advanz, by the FDA and other regulatory agencies and commercial launch of its product candidates, the timing of the announcement of clinical study results, the commencement of patient studies, regulatory applications, approvals and market launches, and the estimated size of the total addressable market of Alvotech's pipeline products. In some cases, you can identify forward-looking statements by terminology such as 'may', 'should', 'expect', 'intend', 'will', 'estimate', 'anticipate', 'believe', 'predict', 'potential' or 'continue', or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech's control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the ability to reach development milestones under commercial partnership agreements including the partnership with Advanz; (2) the ability to raise substantial additional funding, which may not be available on acceptable terms or at all; (3) the ability to maintain stock exchange listing; (4) changes in applicable laws or regulations; (5) the possibility that Alvotech may be adversely affected by other economic, business, and/or competitive factors; (6) Alvotech's estimates of expenses and profitability; (7) Alvotech's ability to develop, manufacture and commercialize the products and product candidates in its pipeline; (8) the ability of Alvotech or its partners to respond to inspection findings and resolve deficiencies to the satisfaction of the regulators; (9) actions of regulatory authorities, which may affect the initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; (10) the ability of Alvotech or its partners to enroll and retain patients in clinical studies; (11) the ability of Alvotech or its partners, including Advanz, to gain approval from regulators for planned clinical studies, study plans or sites; (12) the ability of Alvotech's partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; (13) Alvotech's ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; (14) the success of Alvotech's current and future collaborations, joint ventures, partnerships or licensing arrangements, including the partnership with Advanz; (15) Alvotech's ability, and that of its commercial partners, including Advanz, to execute their commercialization strategy for approved products; (16) Alvotech's ability to manufacture sufficient commercial supply of its approved products; (17) the outcome of ongoing and future litigation regarding Alvotech's products and product candidates; (18) the potential impact of the ongoing COVID-19 pandemic on the FDA's review timelines, including its ability to complete timely inspection of manufacturing sites; (19) the impact of worsening macroeconomic conditions, including rising inflation and interest rates and general market conditions, war in Ukraine and global geopolitical tension, and the ongoing and evolving COVID-19 pandemic on the Alvotech's business, financial position, strategy and anticipated milestones; and (20) other risks and uncertainties set forth in the sections entitled 'Risk Factors' and 'Cautionary Note Regarding Forward-Looking Statements' in documents that Alvotech may from time to time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed. The recipient agrees that it shall not seek to sue or otherwise hold Alvotech or any of its directors, officers, employees, affiliates, agents, advisors, or representatives liable in any respect for the provision of this communication, the information contained in this communication, or the omission of any information from this communication. Advanz Pharma Forward Looking Statements Certain statements in this press release are forward-looking statements. These statements may be identified by words such as 'anticipate', 'expectation', 'belief', 'estimate', 'plan', 'target', 'project', 'will', 'may', 'should' or 'forecast' and similar expressions, or by their context. Although Advanz Pharma believes that these assumptions were reasonable when made, by their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. Actual results may differ from those set forth in the forward-looking statements as a result of various factors (including, but not limited to, future global economic conditions, changed market conditions affecting the industry, intense competition in the markets in which Advanz Pharma operates, costs of compliance with applicable laws, regulations and standards, diverse political, legal, economic and other conditions affecting Advanz Pharma's markets, and other factors beyond the control of Advanz Pharma. Neither Advanz Pharma nor any of its directors, officers, employees, advisors, or any other person is under any obligation to update or keep current the information contained in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak of the date of this press release. Statements contained in this press release regarding past trends or events should not be taken as a representation that such trends or events will continue in the future. No obligation is assumed to update any forward-looking statements. The information contained in this press release is provided as at the date of this document and is subject to change without notice. MEDIA CONTACTS Alvotech Global Communications and Investor Relations Benedikt Stefansson [email protected] Advanz Pharma Global Corporate Communications Courtney Baines [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.

Forbes

26 minutes ago

• Forbes

Six Ways To Advance Modern Architecture For AI Systems

View of the clouds reflected in the curve glass office building. 3d rendering These days, many engineering teams are coming up against a common problem – basically speaking, the models are too big. This problem comes in various forms, but there's often a connecting thread and a commonality to the challenges. Project are running up against memory constraints. As parameters range into the billions and trillions, data centers have to keep up. Stakeholders have to look out for thresholds in vendor services. Cost is generally an issue. However, there are new technologies on the horizon that can take that memory footprint and compute burden, and reduce them to something more manageable. How are today's innovators doing this? Let's take a look. Input and Data Compression First of all, there is the compression of inputs. You can design a loss algorithm to compress the model, and even run a compressed model versus the full one; compression methodologies are saving space when it comes to specialized neural network function. Here's a snippet from a paper posted at Apple's Machine Learning Research resource: 'Recently, several works have shown significant success in training-free and data-free compression (pruning and quantization) of LLMs achieving 50-60% sparsity and reducing the bit-width down to 3 or 4 bits per weight, with negligible perplexity degradation over the uncompressed baseline.' That's one example of how this can work. This Microsoft document looks at prompt compression, another component of looking at how to shrink or reduce data in systems. The Sparsity Approach: Focus and Variation Sometimes you can carve away part of the system design, in order to save resources. Think about a model where all of the attention areas work the same way. But maybe some of the input area is basically white space, where the rest of it is complex and relevant. Should the model's coverage be homogenous or one-size-fits-all? You're spending the same amount of compute on high and low attention areas. Alternately, people engineering the systems can remove the tokens that don't get a lot of attention, based on what's important and what's not. Now in this part of the effort, you're seeing hardware advances as well. More specialized GPU and multicore processors can have an advantage when it comes to this kind of differentiation, so take a look at everything that makers are doing to usher in a whole new class of GPU gear. Changing Context Strings Another major problem with network size is related to the context windows that systems use. If they are typical large language systems operating on a sequence, the length of that sequence is important. Context means more of certain kinds of functionality, but it also requires more resources. By changing the context, you change the 'appetite' of the system. Here's a bit from the above resource on prompt compression: 'While longer prompts hold considerable potential, they also introduce a host of issues, such as the need to exceed the chat window's maximum limit, a reduced capacity for retaining contextual information, and an increase in API costs, both in monetary terms and computational resources.' Directly after that, the authors go into solutions that might have broad application, in theory, to different kinds of fixes. Dynamic Models and Strong Inference Here are two more big trends right now: one is the emergence of strong inference systems, where the machine teaches itself what to do over time based on its past experience. Another is dynamic systems, where the input weights and everything else changes over time, rather than remaining the same. Both of these have some amount of promise, as well, for helping to match the design and engineering needs that people have when they're building the systems. There's also the diffusion model where you add noise, analyze, and remove that noise to come up with a new generative result. We talked about this last week in a post about the best ways to pursue AI. Last, but not least, we can evaluate traditional systems such as digital twinning. Twinning is great for precise simulations, but it takes a lot of resources – if there's a better way to do something, you might be able to save a lot of compute that way. These are just some of the solutions that we've been hearing about and they dovetail with the idea of edge computing, where you're doing more on an endpoint device at the edge of a network. Microcontrollers and small components can be a new way to crunch data without sending it through the cloud to some centralized location. Think about all of these advances as we sit through more of what people are doing these days with AI.

Yahoo

an hour ago

• Yahoo

Can Investing $10,000 in Quantum Computing (QUBT) Stock Turn Into $1 Million by 2035?

Quantum Computing would need to deliver a CAGR of roughly 58.49% to turn $10,000 into $1 million by 2035. Explosive growth in the photonic integrated circuit market could help the company achieve this goal. However, the probability that Quantum Computing will be a millionaire-maker in 10 years is still low. 10 stocks we like better than Quantum Computing › Quantum Computing (NASDAQ: QUBT) is an up-and-coming pioneer in the red-hot field of quantum computing. Could investing $10,000 in this stock turn into $1 million by 2035? It's possible, but the odds are stacked against it. That said, I think there is a viable path for Quantum Computing to make you a millionaire over the next 10 years. Here's what would be required. Quantum Computing's market cap currently hovers around $2.66 billion. Its share price was $18.88 at the market close on June 20, 2025. An investment of $10,000 would buy 529 shares at that price, with $12.48 left over. The company's share price would need to grow 100x to $1,888 for a $10,000 initial investment (assuming you didn't buy any fractional shares) to be worth $1 million in a decade. That reflects a compound annual growth rate (CAGR) of roughly 58.49%. Quantum Computing has certainly demonstrated that it can deliver a much greater annual return than that over the short term. Over the last 12 months, the stock has skyrocketed by more than 3,000%. Sustaining a CAGR of 58.49% over 10 years is a daunting task, but it's not impossible. For example, a $10,000 investment in Nvidia in 2015 would be worth over $2.6 million today. Of course, you would have had to resist the temptation to sell during the GPU stock's huge swings up and down during that period. Now for a more difficult question: How could Quantum Computing stock achieve a CAGR of 58.49% over the next 10 years? To answer this question, we need to understand the company's business. Quantum Computing uses integrated photonics (computing with particles of light) and nonlinear quantum optics to develop quantum computers. The company believes its approach to quantum computing is superior to rivals' methods that use superconducting, trapped-ion, and annealing architectures. Photons' advantages include lower energy consumption, faster processing, and scalability. The photonic integrated circuit market size in 2024 was around $15 billion. Over the next five years, this market is projected to expand by a CAGR of 20.5% to $38.4 billion. While that is an impressive growth rate, it isn't enough to propel Quantum Computing stock 100x higher. But Quantum Computing could grow significantly faster than the overall photonic integrated circuit market. The company's thin film lithium niobate wafers, which it believes will be "the silicon of the future," could make it possible. Also, the photonic integrated circuit market's growth could accelerate beyond 2029. I could envision this occurring if the adoption of the technology in areas such as artificial intelligence (AI), autonomous vehicles, and high-performance computing takes off in a huge way. It's quite possible that investing $10,000 in Quantum Computing stock could make you a millionaire over the next 10 years. But how probable is this scenario? The odds aren't great. For one thing, Quantum Computing's photonics technology might be surpassed by approaches that prove to be even better. Many of the companies investing heavily in developing quantum computers have deep pockets, including Google parent Alphabet, Amazon, IBM, Microsoft, and Nvidia. Other rising stars in the quantum computing industry, such as IonQ, D-Wave Quantum, and Rigetti Computing, could potentially be bigger winners than Quantum Computing. Perhaps progress in advancing quantum computing technology won't be fast enough to support the market growth required for Quantum Computing to be a millionaire-maker. I suspect that won't be the case, but I wouldn't rule it out. The good news for investors, though, is that Quantum Computing doesn't have to turn an initial $10,000 into $1 million by 2035 to still deliver exceptional returns. Before you buy stock in Quantum Computing, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Quantum Computing wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Keith Speights has positions in Alphabet, Amazon, and Microsoft. The Motley Fool has positions in and recommends Alphabet, Amazon, International Business Machines, Microsoft, and Nvidia. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Can Investing $10,000 in Quantum Computing (QUBT) Stock Turn Into $1 Million by 2035? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data